Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M. Kaufmann, Sibylle Loibl(Goethe University Frankfurt), Jean‐Yves Pierga(Université Paris Cité), William R. Miller(Houston Methodist), A. U. Buzdar(The University of Texas MD Anderson Cancer Center), Carsten Denkert(Philipps University of Marburg), Andreas Makris(Institute of Cancer Research), Marco Colleoni(European Institute of Oncology), Vered Stearns(Johns Hopkins University), Hervé Bonnefoi, Raimund Jackesz(Goethe University Frankfurt), Rainer Souchon, Harry D. Bear(Virginia Commonwealth University), Semiglazov Vf(Institute of Oncology NN Petrov), Andreas Schneeweiß(German Cancer Research Center), Paul McGale, W. Eiermann(Ludwig-Maximilians-Universität München), Gϋnter von Minckwitz(German Breast group), Michael Untch(Helios Kliniken)
Cited by 389
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k